Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients
without driver mutation. However, few drugs could be selected when diseases progressed …

In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Background Apatinib, a small‐molecule inhibitor of vascular endothelial growth factor
receptor 2 (VEGFR‐2), has proven to be effective and safe for treating patients with …

Purpose Platinum-based doublet chemotherapy and radiotherapy are the standard
treatment option in advanced squamous cell carcinoma patients. However, few agents could …

7548 Background: Apatinib is an oral, small molecular tyrosine-kinase inhibitor (TKI)
targeting vascular endothelial growth factor receptor (VEGFR). Phase II study has showed …

Background: Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular
endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate …

Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against
EGFR-TKI resistance in lung adenocarcinoma (LA) patients. Here, we investigate the clinical …

Background This phase I trial was primarily conducted to determine the maximum tolerated
dose (MTD) of apatinib combined with docetaxel in advanced lung adenocarcinoma patients …

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: C... : Medicine The Use of Apatinib
in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature : Medicine Log …

Objectives Apatinib exhibits broad-spectrum antitumor activities by selectively inhibiting
vascular endothelial growth factor receptor-2. This study evaluated the efficacy and safety of …